Saturday, January 10, 2015

Macula Conference

Revere Hotel, Boston

7:30 - 8:00 a.m.
Breakfast and Registration
Space 57

8:00 - 8:10 a.m.
Welcome Remarks - course directors 
Theater 1

Jay S. Duker, M.D.
New England Eye Center/Tufts Medical Center

Dean Eliott, M.D.
Massachusetts Eye and Ear

Jeffrey S. Heier, M.D.
Ophthalmic Consultants of Boston

8:10 - 9:40 a.m.
Section 1 - Ocular Imaging
Time will be allotted after each presentation for open discussion. Audience participation is encouraged.
Moderator: Jay S. Duker, M.D.
New England Eye Center/Tufts Medical Center
Theater 1

8:10 - 8:25 a.m.
Idiopathic Multifocal Choroiditis: Imaging
Lawrence A. Yannuzzi, M.D.
Manhattan Eye, Ear & Throat Hospital

8:25:- 8:40 a.m.
Evolution of Type 3 Neovascularization and its Association with PED in AMD using SD-OCT Analysis
David Sarraf, M.D.
Jules Stein Eye Institute

8:40 - 8:55 a.m.
New Multimodal Imaging Findings in Central Serous Chorioretinopathy
K. Bailey Freund, M.D.
Vitreous Retina Macula Consultants of New York

8:55- 9:10 a.m.
How I Image Dry AMD Patients
Peter Kaiser, M.D.
Cole Institute, Cleveland Clinic

9:10 - 9:25 a.m.
Introduction to OCTA: Principles and Hardware
Richard F. Spaide, M.D.
Vitreous-Retina-Macula Consultants of New York

9:25 - 9:40 a.m.
OCTA: Clinical Utility
SriniVas R. Sadda, M.D.
Doheny Eye Institute

9:40 - 10:10 a.m.
Break and Visit Exhibits
Space 57

10:15 - 11:45 a.m.
Section 2 - Ocular Tumors and Special Topics
Time will be allotted after each presentation for open discussion. Audience participation is encouraged.
Moderator: Evangelos Gragoudas, M.D.
Massachusetts Eye and Ear
Theater 1

10:15 - 10:30 a.m.
Primary Retinal Vascular Tumors
William Mieler, M.D.
Illinois Eye and Ear Infirmary

10:30 - 10:45 a.m.
Fine Points in Differentiation of Coats Disease from Retinoblastoma
Jerry A. Shields, M.D.
Wills Eye Hospital

10:45 - 11:00 a.m.
Fascinating Intraocular Tumors to Wet your Appetite: Vasoproliferative Tumors, Retinal Metastasis, Rpe Tumors, and Sclerochoroidal Calcification
Carol Shields, M.D.
Wills Eye Hospital

11:00 - 11:15 a.m.
Retinoblastoma Treatment in 2015
David H. Abramson, M.D., FACS
Memorial Sloan-Kettering Cancer Center

11:15 - 11:30 a.m.
Vitreo-retinal Surgical Management in Ocular Oncology
Timothy Murray, M.D., M.B.A.
Murray Ocular Oncology and Retina

11:30 - 11:45 a.m.
Personalized Management of Uveal Melanoma in the Genomic Era
J. William Harbour, M.D.
Bascom Palmer Eye Institute

11:45 a.m. - 12:45 p.m.
Lunch and Visit Exhibits
Space 57

12:50 - 2:25 p.m.
Section 3 - Management of Diabetic Retinopathy and Retinal Vein Occlusion
Time will be allotted after each presentation for open discussion. Audience participation is encouraged.
Moderator: Dean Eliott, M.D.
Massachusetts Eye and Ear
Theater 1

12:50 - 1:25 p.m.
Keynote: Understanding Recent Clinically Relevant Results from the Diabetic Retinopathy Clinical Research Network

12:50 - 1:00 p.m.
Aflibercept vs. Bevacizumab vs. Ranibizumab for Diabetic Macular Edema: Vision Outcomes
John A. Wells, M.D.
Palmetto Retina Center

1:00 - 1:10 p.m.
Aflibercept vs. Bevacizumab vs. Ranibizumab for Diabetic Macular Edema: OCT and Safety Outcomes
Lee M. Jampol, M.D.
Northwestern University Feinberg School of Medicine

1:10 - 1:25 p.m.
Aflibercept vs. Bevacizumab vs. Ranibizumab for Diabetic Macular Edema: Considerations for Clinical Care
Neil M. Bressler, M.D.
The Wilmer Eye Institute

1:25 - 1:40 p.m.
Updates on the Role of Aflibercept in the Management of DME
Diana V. Do, M.D.
Truhlsen Eye Institute

1:40 - 1:55 p.m.
The Effect of 2mg versus 0.5mg Ranibizumab and the Effect of Scatter Photocoagulation for Macular Edema Due to Retinal Vein Occlusion, the RELATE Study
Peter A. Campochiaro, M.D.
The Wilmer Eye Institute

1:55 - 2:10 p.m.
Pharmacotherapeutic Agents in Development for Diabetic Macular Edema
Quan Dong Nguyen, M.D. M.Sc.
Truhlsen Eye Institute

2:10 - 2:25 p.m.
Discussion

2:25 - 2:55 p.m.
Break and Visit Exhibits
Space 57

3:00 - 5:00 p.m.
Section 4 - Current and Future Approaches to AMD Therapy
Time will be allotted after each presentation for open discussion. Audience participation is encouraged.
Moderator: Jeffrey S. Heier, M.D.
Ophthalmic Consultants of Boston
Theater 1

3:00 - 3:15 p.m.
Which Drug and Why: anti-VEGF agents for Neovascular AMD
David M. Brown, M.D.
Retina Consultants Of Houston

3:15 - 3:30 p.m.
What are the Risks of Using anti-VEGF Agents
Daniel Martin, M.D.
Cole Eye Institute/Cleveland Clinic

3:30- 3:45 p.m.
Dosing Regimens for Neovascular AMD
Carl D. Regillo, M.D., FACS
Wills Eye Hospital

3:45 - 4:00 p.m.
Emerging Therapies for Neovascular AMD
Jason S. Slakter, M.D.
Vitreous-Retina-Macula Consultants of New York

4:00 - 4:15 p.m.
Gene Therapy and Cell-based Therapies for Atrophic AMD
Allen C. Ho, M.D.
Wills Eye Hospital

4:15 - 4:30 p.m.
Will We Ever Have a Treatment for Dry AMD?
Carmen A. Puliafito, M.D., M.B.A.
Keck School of Medicine, USC

4:30 - 4:45 p.m.
Is the time right for genetic testing in AMD?
Carl Awh, M.D.
Tennessee Retina Associates

4:45 - 5:00 p.m.
Summary & Plans for Macula 2016
Joan W. Miller, M.D., FARVO
Mass Eye and Ear

6:30 – 9:30 p.m.
Reception and Dinner
InterContinental Hotel